Angiotensin II and nitric oxide belong to important factors in the functional and structural changes of vessel wall, leading to its increased stiffness. We investigated, whether common mutations of angiotensin II type 1 receptor (AGTR 1 ) and endothelial nitric oxide synthase (eNOS) are associated with increased arterial stiffness. Two polymorphisms, A 1166 C of AGTR 1 and T 786 C of Enos, were estimated in a random, general population-based sample of 250 subjects. Arterial stiffness was measured using Sphygmocor as aortic (carotid-femoral) and peripheral (femoral-tibial) pulse wave velocities (PWV). Carriers of 3-4 mutant alleles from both polymorphisms, that is, homozygous for both mutations or homozygous for one and heterozygous for the second one, showed significantly higher peripheral PWV (17.9272.40) than those with none or only 1-2 mutant alleles (12.3770.51; Po0.003). Carriers of 3-4 mutant alleles had three times higher risk of having increased peripheral PWV (X13.63 m s
Introduction
Progressive stiffening is natural part of vascular ageing. Several epidemiological studies reported that increased arterial stiffness predicts mortality and morbidity, independently of other cardiovascular risk factors. 1, 2 On the other hand, recent evidence suggested that arterial stiffness could be modified by appropriate treatment, independently of blood pressure (BP). The new Conduit Artery Function Evaluation study reported that, in contrast to bblockers and diuretics, treatment with calcium antagonist combined with angiotensin-converting enzyme (ACE) inhibitor significantly decreased derived central BP (a clinical consequence of increased aortic rigidity), whereas the effect on brachial BP was in both treatment arms nearly similar. 3 Progressive chronic arterial stiffening has been pathophysiologically explained by fatigue and fractures of the elastin fibres and by the transfer of stress to more rigid collagen fibres. Turnover (synthesis and degradation) of key extracellular matrix components (elastin, collagen and calcium) is also impaired. 4, 5 In muscular-type arteries, arterial stiffening is moreover determined by degree of smooth muscle hypertrophy and smooth muscle tone which represent structural and functional component of stiffness, respectively. 6 Age and BP are major determinants of arterial rigidity. Additionally, local hormones may also play a crucial role in the compliance of arterial wall. Angiotensin II, the potent vasoconstrictor, mediates through its type 1 receptor (AGTR 1 ) growth-promoting and pro-inflammatory processes in extracellular matrix, 7, 8 independently of BP. Endothelium-derived nitric oxide (NO), which is synthesized locally from L-arginine by endothelial nitric oxide synthase (eNOS), seems to have, besides vasodilation, virtually inverse effects on arterial stiffness than angiotensin II. In experiments, inhibition of basal NO synthesis by N-monomethyl-Larginine (L-NMMA) increased, 9, 10 while NO donor nitroglycerine decreased arterial stiffness.
The genes coding for the AT1 receptor and eNOS have been found to be polymorphic. The relationships of their alleles to hypertension and other cardiovascular abnormalities have been investigated in several studies. [12] [13] [14] [15] In the present study we aimed to establish whether stiffness of central or peripheral large arteries is associated with common polymorphisms of AGTR 1 and of eNOS (that is, A 1166 C and T 786 C, respectively) and moreover, whether both mutations have any additive effect on arterial stiffness, if combined.
Methods
The study population consisted of random general population sample. A survey of risk factors was undertaken in 2000-2001 as a part of Czech post-MONICA (MONItoring CArdiovascular disease) study. 16 One per cent of residents of City of Pilsen, aged 25-65 years, was selected (stratified by age and sex) from the General Health Insurance Registry. A total of 1009 subjects, 488 males and 522 females, mean age 48.1, responded to the survey. A random 25% sub-sample of subjects, free of any manifest heart disease, was evaluated in the present study.
All study procedures were done according to Good Clinical Practice regulation and were approved by the local ethical committee. The informed consent was obtained from all subjects and all personal data were stored under the provisions of the Czech Data Protection Act. All responders were interviewed and examined by standardized methods using WHO MONICA standard manual. Methods of interview were described in details elsewhere. 16 Briefly, information on personal and demographic characteristics, personal and family history of coronary heart disease, lifestyle and current pharmacotherapy was obtained at interview. Following standardized examinations were performed: height and weight in light indoor clothes without shoes by DETECTO 20 (Webb City, MO, USA) scale and measuring stick. BP was measured three times in the sitting position on the right arm using standard mercury sphygmomanometers to the nearest 2 mm Hg; appropriate cuff size was used.
Large artery properties were measured using the semi-automatic Sphygmocor device (AtCor Medical Ltd, Australia); the methods of measurement are described in detail in our previous reports. 17, 18 Arterial stiffness was assessed by pulse wave velocity (PWV), measured in supine position in the aorta, that is, between carotid and femoral arteries (aortic PWV, APWV) and in the lower extremity, that is, between femoral and dorsalis pedis or tibialis posterior arteries (peripheral PWV, PPWV). Consecutive registrations of the pulse waves are electrocardiogram gated and thus, the time shift between the appearance of wave at the first and the second sites can be calculated. The distance between the two sites was measured on the body surface; to determine aortic PWV, we measured the distance from the jugular fossa to the pulsation of the femoral artery in the groin subtracting, from this distance, the distance from the jugular fossa to carotid pulsation since the pulse runs here in the direction opposite to that in the aorta. The average of measurements over a period of 8 s (9-10 cardiac cycles) was calculated after the exclusion of extreme values. The methods were shown to have good reproducibility. 19 Venous blood samples were drawn in fasting state, and frozen serum samples, stored at À801, were used for biochemical laboratory analyses in the series. The laboratory examinations, including assessment of total (TCHOL) and high-density lipoprotein cholesterol (HDL), triglycerides (TG) were provided by the central laboratories of survey (Institute of Clinical and Experimental Medicine, Prague) using Cobas Mira analyser (Basel, Switzerland) and commercially available kits of the same provenience. Glucose levels were analysed by enzymatic method in the same laboratory using Lachema (Brno, Czech Republic) standard kits. Low-density lipoprotein cholesterol (LDL) was calculated by Friedewald equation, that is, LDL ¼TCHOLÀHDLÀ(TG/5). Serum total homocysteine concentrations was estimated by commercial FPIA kits and automatic analysers (AxSYM, Abbott Laboratories, Wiesbaden, Germany). Variation for all these measurements was less than 1.5%.
The eNOS and AGTR 1 gene polymorphisms were assessed by the polymerase chain reaction-restriction fragment length polymorphism methodology, as described elsewhere. 20, 21 Genomic DNA was isolated from peripheral blood leucocytes by standard extraction method using commercial DNA isolation kits (Sigma, Saint Louis, MO, USA). Two mutation were assessed: T 786 C (eNOS) and A 1166 C (AGTR 1 ) using REDTaq DNA polymerase (Sigma), BanII (Eco24I) and MspI enzymes (Biogen, Prague, Czech Republic).
The study was designed as a cross-sectional analysis. Statistical analysis of the data was done using Stata 6. The significance of differences among specific groups was evaluated by Fisher's w 2 -test for categorical variables and by analysis of variance or Mann-Whitney U-test for continuous variables. Multiple logistic regression was used to ascertain the association followed polymorphisms and large artery properties after adjustment for potential confounders.
Results
A total of 250 subjects, aged 48.0370.70 (mean7 s.e.m.), 121 males and 129 females, were evaluated in the present study; other characteristics of the study sample are given in Table 1 . The whole sample was divided separately by T 786 C (eNOS) and A 1166 C (AGTR 1 ) polymorphisms ( Table 2 ). The alleles of both polymorphisms were distributed according to the Hardy-Weinberg equilibrium, 15.2 and 10.0% of subjects were homozygous for T 786 C and A 1166 C mutations, respectively, while 42.0 and 35.2% heterozygous. A statistically significant increasing trend in PPWV with number of mutant alleles was found with both T 786 C and A 1166 C polymorphisms (Po0.05 and Po0.02, respectively). No significant associations were found between both mutations and APWV, BP and other standard cardiovascular risk factors. The influence of combination of both mutations on arterial stiffness was further studied. The whole sample was divided into nine subgroups by all possible combinations of both polymorphisms and the statistical differences were estimated among three groups, A, B and C ( Figure 1 ). Combination incorporating both mutations in homozygous state or 1 homozygous þ 1 heterozygous mutation (3-4 mutant alleles from both polymorphisms, group C, black bars) produced markedly higher PPWV than combination of wild types or any combination which included only heterozygous mutations (group A, white bars,). On the other hand, combination of single homozygous mutation from one polymorphism with wild-type genotype of second polymorphism did not produce any increase in PPWV (group B, stripped bars). These differences remained significant also after adjustment for potentially confounding factors (age, gender, current smoking, BP, lipid profile, glucose and homocysteine) in multiple logistic regressions, where increased PPWV (over 13.62 m s À1 , that is, in top quartile) were used as dependent variable (Table 3) . Carriers of 3-4 mutant C alleles had more than three times higher risk of increased PPWV than those bearing 0-2 mutant C alleles.
No such associations were found for APWV, and moreover subjects in all three groups (A, B or C) did not differ in other potentially confounding parameters, such as age, BP, anti-hypertensive treatment and so on (Table 4) .
Discussion
The main finding of our study is that there is probably an interaction between AGTR 1 and eNOS genotype in terms of stiffening of muscular-type arteries. Both T 786 C mutation of eNOS and A 1166 C mutation of AGTR 1 had in our study potential to increase gradually stiffness of lower-limb arteries, measured by pulse wave velocity, and their effect was synergic. Carriers of at least three mutant C alleles from both polymorphisms (that is, homozygous þ homozygous or homozygous þ heterozygous) showed by about 50% higher PWV of peripheral arteries than wild-type or only heterozygous carriers. Presence of at least three mutant C alleles independently increased risk of high PPWV by more than three times and remained significant when adjusted for covariates potentially affecting PWV. On the other hand, homozygous mutation of any genotype alone (CC of T 786 C or A 1166 C) did not influence peripheral arterial stiffness when combined with normal, wild-type genotype from the second polymorphism (that is, CC þ AA or TT þ CC combination).
Although the physiological roles of AGTR 1 and eNOS are well defined, particular mechanisms by which their genetic polymorphisms may increase arterial stiffness remain unclear. On the other hand, it is already evident, that renin-angiotensin system and endothelium interact on several levels. Angiotensin II exerts its vasoconstrictory and trophic actions on smooth muscle cells via AGTR 1 receptors. 7, 8 However, it also stimulates the release of endothelium-derived NO with vasodilatory and anti-proliferative properties via same receptor in endothelial cells. 22, 23 Thus, the angiotensin II-induced release of NO counterbalances the inverse direct properties of this peptide. The interaction between angiotensin II and eNOS in terms of arterial stiffening demonstrates experimental study by Fitch et al. 24 Treatment with angiotensin II or inhibition of eNOS by L-NAME (N-(omega)-nitro-L-arginine methyl ester) did not increase vascular stiffness in mice when administered separately, however, in combination, it did significantly increase PWV (in vivo), maximal passive stiffness (ex vivo) and, moreover, it increased collagen and decreased elastin content in aortic wall. 24 Similarly, Alvarez et al. 21 reported that T 786 C mutation of eNOS significantly increased the risk of premature manifestation of coronary heart disease by more than two times, if combined with ACE I/D polymorphism. Only few studies, performed on hypertensive subjects, dealt with association between aortic stiffness and polymorphism of AGTR 1 . Their results remain equivocal. Four studies reported that presence of A 1166 C allele of AGTR 1 polymorphism was associated with increased aortic stiffness. [25] [26] [27] [28] However, study by Gardier et al. 29 with very similar design showed an inverse association: not C, but A allele carriers with hypertension had higher aortic stiffness. Even less evidence exists about the role of eNOS polymorphisms in arterial stiffening. It has been recently reported that G allele carriers of second common polymorphism of eNOS (G 894 T) showed significantly higher distal arterial stiffness, than those with wild-type genotype, however only in African Americans, and not in white Americans. 30 CC genotype of T 786 C (that is, polymorphism evaluated in the present study) seems to be an independent risk factor of carotid atherosclerosis, 15 however, we are not aware of any study concerning the stiffness of large arteries. We can only speculate why both eNOS and AGTR 1 polymorphisms influenced in our sample peripheral, but not central large arteries. It is evident, that the dynamics of vascular ageing are different in central elastic and peripheral muscular arteries. 31, 32 Thus, also the effect of other individual risk factors, both genetic and environmental, is not uniform, but depends on vascular territory. The key point could be hypothetically that NO influenced predominantly smooth muscle tone, a functional determinant of vessel wall stiffness, and therefore, its effect was more pronounced in muscular-type arteries. This type of artery is likely to be less dependent on changes in collagen/elastin balance than elastic-type aortic bed. Wilkinson et al. 10 reported that inhibition of eNOS by L-NMMA was followed by a significant increase in stiffness of ovine iliac artery (a model of muscular artery) independently of BP, while another study dealing with aortic stiffness did not find any additional Ang II, eNOS and arterial stiffness O Mayer Jr et al specific effect of eNOS inhibition which would go beyond the effect mediated by BP changes. 9 Our study population differed in many ways from above-mentioned studies, [25] [26] [27] [28] reporting an association between AGTR 1 mutation and increased aortic stiffness. Namely, the present study was based on a random sample of general population. Our study subjects were younger and had markedly lower average BP, that is, their age-and BP-related changes of central elastic arteries were less advanced. This may play a role; Benetos et al. 26 reported a strong association between A 1166 C polymorphism and APWV, but only in hypertensives and not in normotensives, and furthermore, more pronounced in older (aged over 55 years) than in younger subjects.
Our study had several limitations, usual in such type of cross-sectional genetic studies. Namely, in spite that our sample size was enough powered to detect the differences in main parameter (that is, PPWV), we cannot further divide the sample into subgroups by other risk factors and treatment to evaluate the possible interaction with these factors. We can only confirm the independency of PPWVgenotype association by multiple regressions with adjustment for conventional confounders. Nineteen subjects (that is, 7.6%) were treated with ACE inhibitors in our sample, but the groups divided according to the genotype combination studied (A, B or C) did not differ in the proportion of ACE inhibitors treatment. Moreover, the treatment with ACEI inhibitors did not enter significantly the regressions as independent factor. Therefore, these subjects were not excluded from final evaluation. No subjects was treated with AGTR 1 antagonists (sartans) or nitrates in our sample.
In conclusion, we found that combination of AGTR 1 and eNOS mutation increased potently stiffness of peripheral muscular-type arteries. Carriers of mutant alleles of both polymorphisms may be at high cardiovascular risk, independently of BP and other risk factors. Furthermore, our results indicate the importance of studying, besides central arteries, also mechanical properties of peripheral, large-or medium-sized muscular arteries. Abbreviations: ACE, angiotensin-converting enzyme; HDL, high-density lipoprotein. Group A, 0-2 mutant alleles with no mutation in homozygous state (represented by white bars in Figure 1 ); group B, combination of homozygous mutation with wild type (represented by stripped bars in Figure 1 ); group C, 3-4 mutant alleles and no wild-type genotype (represented by black bars in Figure 1 ). Mann-Whitney U-test for continuous and Fisher's w 2 -test for categorical variables.
What is known about topic K Angiotensin II mediates through its type 1 receptor (AGTR1) growth-promoting processes in extracellular matrix and as a potent vasoconstrictor also increases vascular smooth-muscle tone. These processes may pathophysiologically lead to increased stiffness of vessel wall. K Endothelial-derived nitric oxide (NO), which is synthesized locally by endothelial nitric oxide synthase (eNOS), seems to have in experimental studies virtually inverse effects (that is anti-proliferative and vasodilatory) K Both AGTR1 and eNOS are genetically polymorphic.
What this study adds
K In spite of opposite vascular effect of studied systems, genetic polymorphisms of both AGTR1 and eNOS were associated with increased stiffness of muscular-type arteries of lower extremity. K However, the increased stiffness expressed only in carriers of at least three mutant alleles, that is homozygous for both mutations or homozygous for one and heterozygous for the second one. K Combination of single homozygous mutation from one polymorphism with wild-type genotype of second polymorphism did not produce any increase in peripheral artery stiffness.
